Cover Image
市場調查報告書

嚴重乾癬- 開發平台分析

Severe Psoriasis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251619
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
嚴重乾癬- 開發平台分析 Severe Psoriasis - Pipeline Review, H2 2015
出版日期: 2015年11月30日 內容資訊: 英文 103 Pages
簡介

乾癬是常見的皮膚病,特徵是皮膚上產生一層銀色鱗屑,引起發炎的帶狀皮膚產生的肥厚斑點。身體有10%以上覆有銀色皮屑便稱作嚴重乾癬。症狀有銀色鱗屑下皮膚產生紅色的斑點,小小的飛屑性,出血或乾粗的肌膚,發癢或刺痛感、關節腫脹和發硬等。致病因素有壓力、氣候變化、連鎖球菌或HIV感染、淺傷、身體性疾病,或是服用了鋰類的特定藥物或β- 阻斷劑等。

本報告提供重病乾癬的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

嚴重乾癬概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

企業開發中的產品

治療藥的開發企業

  • Johnson & Johnson
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • ApoPharma Inc.
  • Novartis AG
  • Pfizer Inc.
  • Idera Pharmaceuticals, Inc.
  • Almirall, S.A.
  • Syntrix Biosystems, Inc.
  • Vascular Biogenics Ltd.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型
  • ■藥物簡介
  • brodalumab
  • ixekizumab
  • secukinumab
  • tildrakizumab
  • LAS-41008
  • adalimumab biosimilar
  • baricitinib
  • VB-201
  • aminopterin sodium
  • orilotimod
  • BI-655066
  • IMO-8400
  • PF-04965842
  • AMG-811
  • guselkumab

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7343IDB

Summary

Global Markets Direct's, 'Severe Psoriasis - Pipeline Review, H2 2015', provides an overview of the Severe Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Severe Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Severe Psoriasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Severe Psoriasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Severe Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Severe Psoriasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Severe Psoriasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Severe Psoriasis Overview
  • Therapeutics Development
    • Pipeline Products for Severe Psoriasis - Overview
  • Severe Psoriasis - Therapeutics under Development by Companies
  • Severe Psoriasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Severe Psoriasis - Products under Development by Companies
  • Severe Psoriasis - Companies Involved in Therapeutics Development
    • Almirall, S.A.
    • AstraZeneca Plc
    • Boehringer Ingelheim GmbH
    • Celgene Corporation
    • Eli Lilly and Company
    • Forward Pharma A/S
    • Galectin Therapeutics, Inc.
    • Idera Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Sandoz International GmbH
    • Sun Pharma Advanced Research Company Ltd.
    • Syntrix Biosystems, Inc.
    • Valeant Pharmaceuticals International, Inc.
  • Severe Psoriasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • aminopterin sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • baricitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BI-655066 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • brodalumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CC-90005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COVA-322 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dimethyl fumarate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dimethyl fumarate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • guselkumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-118 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMO-8400 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ixekizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-1095 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • orilotimod potassium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tildrakizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • toreforant tartrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Severe Psoriasis - Recent Pipeline Updates
  • Severe Psoriasis - Dormant Projects
  • Severe Psoriasis - Discontinued Products
  • Severe Psoriasis - Product Development Milestones
    • Featured News & Press Releases
      • Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Severe Psoriasis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Severe Psoriasis - Pipeline by Almirall, S.A., H2 2015
  • Severe Psoriasis - Pipeline by AstraZeneca Plc, H2 2015
  • Severe Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Severe Psoriasis - Pipeline by Celgene Corporation, H2 2015
  • Severe Psoriasis - Pipeline by Eli Lilly and Company, H2 2015
  • Severe Psoriasis - Pipeline by Forward Pharma A/S, H2 2015
  • Severe Psoriasis - Pipeline by Galectin Therapeutics, Inc., H2 2015
  • Severe Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
  • Severe Psoriasis - Pipeline by Johnson & Johnson, H2 2015
  • Severe Psoriasis - Pipeline by Merck KGaA, H2 2015
  • Severe Psoriasis - Pipeline by Sandoz International GmbH, H2 2015
  • Severe Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
  • Severe Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2015
  • Severe Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Severe Psoriasis Therapeutics - Recent Pipeline Updates, H2 2015
  • Severe Psoriasis - Dormant Projects, H2 2015
  • Severe Psoriasis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Severe Psoriasis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top